ARTICLE | Company News

Alchemia, Panther Biotechnology deal

August 10, 2015 7:00 AM UTC

Panther will acquire Alchemia’s Alchemia Oncology Pty Ltd. subsidiary in a deal slated to close by late October. The subsidiary’s portfolio includes the HyACT drug delivery technology and HA-Irinotecan for cancer. This year, Panther plans to submit an IND to FDA for a Phase III trial of HA-Irinotecan, an IV formulation of irinotecan and hyaluronic acid developed using HyACT. The product missed the primary endpoint in a Phase III trial as part of FOLFIRI therapy as second- or third-line treatment of metastatic colorectal cancer (mCRC) (see BioCentury, Nov. 3, 2014). ...